Abstract
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
Bentham Science Disclaimer:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
Current Cancer Drug Targets
Title:Notice of Withdrawal
Volume: 17
Abstract: Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
Bentham Science Disclaimer:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
Export Options
About this article
Cite this article as:
Notice of Withdrawal, Current Cancer Drug Targets 2017; 17 () . https://dx.doi.org/10.2174/1568009617666170623121446
DOI https://dx.doi.org/10.2174/1568009617666170623121446 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy Neoadjuvant Chemotherapy Induces the Appearance of New Copy Number Aberrations in Breast Tumor and is Associated with Metastasis
Current Cancer Drug Targets Emergence of Nanomedicine as Cancer Targeted Magic Bullets: Recent Development and Need to Address the Toxicity Apprehension
Current Drug Discovery Technologies Obesity and Asthma
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry Combination Treatment of Glioblastoma by Low-Dose Radiation and Genistein
Current Radiopharmaceuticals Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges
Current Medicinal Chemistry Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Photoacoustic Detection and Imaging of Cancer Using Nanoparticles as Optical Contrast Agents
Recent Patents on Nanomedicine Effect of Cytostatic Drugs on the mRNA Expression Levels of Ribonuclease κ in Breast and Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Biodistribution, Safety and Organ Toxicity of Docetaxel-Loaded in HER-2 Aptamer Conjugated Ecoflex® Nanoparticles in a Mouse Xenograft Model of Ovarian Cancer
Recent Patents on Nanotechnology Impact of Immune Response on the Use of iPSCs in Disease Modeling
Current Stem Cell Research & Therapy Nanomedical Platform for Drug Delivery in Cancer
Current Organic Chemistry Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets ACP5: Its Structure, Distribution, Regulation and Novel Functions
Anti-Cancer Agents in Medicinal Chemistry